TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small cell lung cancer(r/r SCLC) who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in SCLC.

NCT Number	NCT07246304
Lead Sponsor	TCRCure Biopharma Ltd. Collaborators: The Jinling Hospital
Conditions	Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
Enrollment	24 participants
Start Date	2025-11-30
Primary Completion	2027-11-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-24